Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Mar 25, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2010-03-24$7.08/sh−202,700$1,435,116→ 933,754 total - Sale
Common Stock
2010-03-23$7.02/sh−127,300$893,646→ 1,136,454 total - Sale
Common Stock
2010-03-25$7.00/sh−50,000$350,000→ 883,754 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.